

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 023070-067720US
Client Reference No.: 96-215-3

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


On

14 July 2005

TOWNSEND and TOWNSEND and CREW LLP

By:

Malinda Wej



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LALEH SHAYESTEH et al.

Application No.: 08/905,508

Filed: August 4, 1997

For: GENETIC ALTERATIONS
ASSOCIATED WITH CANCER

Examiner: Jehanne Souaya Sitton

Art Unit: 1634

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The reference cited on attached form PTO/SB/08B is being called to the attention of the Examiner. A copy of the reference [in compliance with the requirements of 1287 OG 163] is enclosed. It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:mcd
Unsaved Document



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	08/905,508		
		Filing Date	August 4, 1997		
		First Named Inventor	Shayesteh, Laleh		
		Art Unit	1634		
		Examiner Name	Jehanne Souaya Sitton		
Sheet	1	of	1	Attorney Docket Number	023070-067720US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	E1	Richard M. Schultz, <i>et al.</i> , "in Vitro and in Vivo Antitumor Activity of the Phosphatidylinositol-3-kinase Inhibitor, Wortmannin," <i>Anticancer Research</i> 15: 1135-1140 (1995)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.